NeuroOne® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
NeuroOne Medical Technologies (NMTC), a medical technology company focused on improving surgical care for neurological disorders, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place both in-person and virtually from September 9-11, 2024.
Chief Operating Officer Chris Volker will deliver a virtual presentation, available on demand starting at 7:00 a.m. ET on Monday, September 9, 2024, and continuing throughout the conference. Investors can register for the conference online to access the presentation. Additionally, registered investors can schedule one-on-one meetings through the conference website or by contacting their H.C. Wainwright representative.
NeuroOne Medical Technologies (NMTC), un'azienda nel settore della tecnologia medica, si è concentrata sul miglioramento delle cure chirurgiche per i disturbi neurologici, e ha annunciato la sua partecipazione alla 26ª Conferenza Annuale Globale sugli Investimenti H.C. Wainwright. L'evento si svolgerà sia in presenza che virtualmente dal 9 all'11 settembre 2024.
Il Chief Operating Officer Chris Volker presenterà una presentazione virtuale, disponibile on demand a partire dalle 7:00 a.m. ET di lunedì 9 settembre 2024, e che continuerà per tutta la durata della conferenza. Gli investitori possono registrarsi online per la conferenza per accedere alla presentazione. Inoltre, gli investitori registrati possono programmare incontri one-on-one tramite il sito web della conferenza o contattando il loro rappresentante H.C. Wainwright.
NeuroOne Medical Technologies (NMTC), una empresa de tecnología médica enfocada en mejorar la atención quirúrgica para trastornos neurológicos, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversión H.C. Wainwright. El evento tendrá lugar tanto en persona como de forma virtual del 9 al 11 de septiembre de 2024.
El Director de Operaciones Chris Volker ofrecerá una presentación virtual, disponible bajo demanda a partir de las 7:00 a.m. ET del lunes 9 de septiembre de 2024, y continuará durante toda la conferencia. Los inversores pueden registrarse en línea para acceder a la presentación. Además, los inversores registrados pueden programar reuniones individuales a través del sitio web de la conferencia o contactando a su representante de H.C. Wainwright.
NeuroOne Medical Technologies (NMTC)는 신경 장애에 대한 외과 치료를 개선하는 데 중점을 둔 의료 기술 회사로, H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 대면 및 가상으로 진행됩니다.
최고 운영 책임자 Chris Volker가 가상 발표를 진행할 예정이며, 이는 2024년 9월 9일 월요일 오전 7시 ET부터 주문형으로 제공되며, 컨퍼런스 기간 동안 계속됩니다. 투자자들은 발표에 접근하기 위해 온라인으로 컨퍼런스에 등록할 수 있습니다. 또한 등록된 투자자는 컨퍼런스 웹사이트를 통해 일대일 미팅을 예약하거나 H.C. Wainwright 대표에게 연락할 수 있습니다.
NeuroOne Medical Technologies (NMTC), une entreprise de technologie médicale axée sur l'amélioration des soins chirurgicaux pour les troubles neurologiques, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur l'Investissement H.C. Wainwright. L'événement se déroulera à la fois en personne et virtuellement du 9 au 11 septembre 2024.
Le directeur des opérations Chris Volker fera une présentation virtuelle, disponible à la demande à partir de 7h00 ET le lundi 9 septembre 2024, et ce, tout au long de la conférence. Les investisseurs peuvent s'inscrire en ligne à la conférence pour accéder à la présentation. De plus, les investisseurs enregistrés peuvent programmer des réunions individuelles via le site Web de la conférence ou en contactant leur représentant H.C. Wainwright.
NeuroOne Medical Technologies (NMTC), ein Medizintechnologieunternehmen, das sich auf die Verbesserung der chirurgischen Versorgung bei neurologischen Erkrankungen konzentriert, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Die Veranstaltung findet sowohl in Präsenz als auch virtuell vom 9. bis 11. September 2024 statt.
Der Chief Operating Officer Chris Volker wird eine virtuelle Präsentation halten, die ab 7:00 Uhr ET am Montag, den 9. September 2024 auf Abruf verfügbar ist und während der gesamten Konferenz fortgesetzt wird. Investoren können sich online für die Konferenz registrieren, um auf die Präsentation zuzugreifen. Darüber hinaus können registrierte Investoren über die Konferenz-Website oder ihren H.C. Wainwright-Vertreter Einzelgespräche planen.
- None.
- None.
EDEN PRAIRIE, Minn., Sept. 05, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its upcoming virtual investor presentation at the H.C. Wainwright 26th Annual Global Investment Conference being held in-person and virtually on September 9-11, 2024.
The Company’s virtual presentation by Chief Operating Officer Chris Volker will be available on demand beginning at 7:00 a.m. ET on Monday, September 9, 2024, through the end of the conference. To access the presentation, investors can register for the conference here. One-on-one meetings are available to registered investors via the conference website or by contacting their H.C. Wainwright representative.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue, "focused on," "committed to" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the transition of manufacturing from sEEG diagnostic electrodes to OneRF electrodes, the addition of new centers for the Company’s limited commercial launch, potential strategic partnership opportunities, continued development of the Company's electrode technology program (including our drug delivery program and spinal cord stimulation program), business strategy, market size, potential growth opportunities, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company's capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
“Caution: Federal law restricts this device to sale by or on the order of a physician”
Contact:
800-631-4030
ir@nmtc1.com
FAQ
When is NeuroOne (NMTC) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for NeuroOne (NMTC) at the H.C. Wainwright conference?
How can investors access NeuroOne's (NMTC) presentation at the H.C. Wainwright conference?
Are one-on-one meetings available with NeuroOne (NMTC) at the H.C. Wainwright conference?
